4-amino-N-cyclopentylbenzenesulfonamide | 436091-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-N-cyclopentylbenzenesulfonamide
• 英文别名: 4-amino-N-cyclopentylbenzene-1-sulfonamide
• CAS: 436091-88-2
• 化学式: C₁₁H₁₆N₂O₂S
• mdl: MFCD04035138
• 分子量: 240.326
• InChiKey: XNPAQSUBTOJSLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-amino-N-cyclopentylbenzenesulfonamide 在 亚硝酸特丁酯 、 溴 、 potassium carbonate 、 copper(ll) bromide 作用下， 以 溶剂黄146 、 乙腈 为溶剂， 反应 34.0h， 生成 N-cyclopentyl-2-(4-ethylpiperazin-1-yl)benzo[d]thiazole-6-sulfonamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS
  [FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'ACTIVATEURS DE PDE4

  摘要：

  The present invention relates to compounds of Formulas A-D, I-IV and Z, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5'-adenosine monophosphate (cAMP).

  公开号：

  WO2022172037A1
• 作为产物：
  描述：

  N-cyclopentyl-4-nitrobenzenesulfonamide 在 palladium 10% on activated carbon 、 氢气 作用下， 反应 1.0h， 生成 4-amino-N-cyclopentylbenzenesulfonamide
  参考文献：
  名称：

  Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors

  摘要：

  Cantharidin and norcantharidin display anticancer activity against a broad range of tumor cell lines. In this study, we have synthesized a series of norcantharidin derivatives and evaluated their cytotoxic effects on four human tumor cell lines together with the genetically normal human diploid fibroblast line WI-38. One of our compounds (1S,4R)-3-((4-(4-(4-fluorophenyl) piperazin-1-ylsulfonyl) phenyl) carbamoyl)-7-oxa-bicyclo[2.2.1] heptane-2-carboxylic acid (12) exhibited potent cytotoxic effects on the tumor cell lines A-549, HepG2, HeLa, and HCT-8, whereas it was less toxic to WI-38 cells than its parent compound, norcantharidin. In addition, this compound inhibited protein phosphatase-1 activity and microtubule formation in HeLa cells, and it also interacts with calf thymus DNA. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.032

文献信息

• [EN] INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4)<br/>[FR] INHIBITEURS DE PROTÉINE 4 CONTENANT UN BROMODOMAINE (BRD4)
  申请人：ZHOU JIA

  公开号：WO2018112037A1

  公开（公告）日：2018-06-21

  Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.

  某些实施例涉及BRD4溴结构域的小分子选择性抑制剂。本文描述的化合物可用于调节支气管NFκB-BRD4轴，该轴在对病毒分子模式的急性中性粒细胞反应中起作用。本文描述的化合物可作为各种人类疾病和病况的预防和治疗药物开发。
• 一种合成氨基-(N-烷基)苯磺酰胺的方法
  申请人：南京理工大学

  公开号：CN106146358B

  公开（公告）日：2018-01-23

  本发明公开了一种合成氨基‑(N‑烷基)苯磺酰胺的方法。包括如下步骤：在反应容器中，加入氨基苯磺酰胺、铱络合物催化剂、碱、化合物醇、溶剂叔戊醇，反应混合物在120‑150 oC下反应数小时后，冷却到室温，旋转蒸发除去溶剂，然后通过柱分离，得到目标化合物。本发明使用商品化的氨基苯磺酰胺和近于无毒的化合物醇为起始原料；反应只生成水为副产物，无环境危害；反应原子经济性高。
• Novel adenosine A3 receptor agonists
  申请人：Baraldi Giovanni Pier

  公开号：US20050250729A1

  公开（公告）日：2005-11-10

  The compounds of the following formula: wherein Ar, R and R 1 have the meanings given in the specification. This series of sulfonamido derivatives with a conserved uronamide group at the 5′ position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido derivatives N-substituted with aliphatic groups (cyclic or linear) or aromatic radicals.

  以下化合物的公式：其中Ar，R和R1具有规范中给出的含义。这一系列的磺酰胺衍生物在5'位置具有保守的糖醛酰胺基团，提供了优越的A3受体亲和力和选择性。这些新的腺苷受体激动剂是磺酰胺衍生物，其N-取代基为脂肪基（环状或线性）或芳香基团。
• NOVEL ADENOSINE A3 RECEPTOR AGONISTS
  申请人：Baraldi Pier Giovanni

  公开号：US20090233878A1

  公开（公告）日：2009-09-17

  The present invention provides compounds of the formula wherein Ar, R and R 1 have a meaning as defined herein in the specification. Compounds of formula (I) are agonists of the A 3 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A 3 adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of behavioral depression, cerebral ischemia, hypotension, chemically induced seizures, inflammatory diseases, asthma, and cancer diseases expressing the adenosine A 3 receptor.

  本发明提供了具有以下公式的化合物，其中Ar，R和R1的含义如本说明书中所定义。公式（I）的化合物是A3腺苷受体的激动剂，因此可用于治疗由A3腺苷受体介导的疾病。因此，公式（I）的化合物可用于治疗行为性抑郁症，脑缺血，低血压，化学诱导的癫痫，炎症性疾病，哮喘和表达腺苷A3受体的癌症疾病。
• Inhibitors of bromodomain-containing protein 4 (BRD4)
  申请人：Zhou Jia

  公开号：US11117865B2

  公开（公告）日：2021-09-14

  Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.

  某些实施方式涉及BRD4溴结构域的小分子选择性抑制剂。本文所述化合物可用于调节支气管NFκB-BRD4轴，其在响应病毒分子模式的急性中性粒细胞反应中发挥重要作用。本文所述化合物可开发为预防和治疗多种人类疾病和状况的药物。